2023
Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretion
2022
Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications
Shah R, Chernausek S, ghormli L, Geffner M, Keady J, Kelsey M, Farrell R, Tesfaldet B, Tryggestad J, Van Name M, Isganaitis E. Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1120-1131. PMID: 36446741, PMCID: PMC10306086, DOI: 10.1210/clinem/dgac663.Peer-Reviewed Original ResearchConceptsYouth-onset type 2 diabetesType 2 diabetesMaternal diabetesHeart rate variabilityGlomerular hyperfiltrationParental diabetesGlycemic controlRate variabilityFuture cardiometabolic diseaseParental diabetes historyYouth-onset T2D.Lower heart rate variabilityRisk of complicationsWorse glycemic controlΒ-cell functionRace/ethnicityDiabetes historyCardiometabolic diseasesDiabetes outcomesPrenatal exposureUS cohortGlycemic outcomesRisk factorsDisease progressionUS Centers
2021
Colonic Fermentation and Acetate Production in Youth with and without Obesity
Galuppo B, Cline G, Van Name M, Shabanova V, Wagner D, Kien CL, Santoro N. Colonic Fermentation and Acetate Production in Youth with and without Obesity. Journal Of Nutrition 2021, 151: 3292-3298. PMID: 34494088, PMCID: PMC8562084, DOI: 10.1093/jn/nxab277.Peer-Reviewed Original ResearchConceptsDe novo lipogenesisLean youthLactulose ingestionGut microbiotaHepatic de novo lipogenesisDevelopment of obesityColonic acetateOral doseIntravenous infusionPeripheral circulationColonic fermentationNovo lipogenesisObesityRate of appearanceAge 15Spearman correlationIngestionLactuloseRegression modelsMicrobiotaLesser degreeComplicationsGroupInfusionFerment carbohydratesLong-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertension
2020
Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers
Ebekozien O, Agarwal S, Noor N, Albanese-O’Neill A, Wong JC, Seeherunvong T, Sanchez J, DeSalvo D, Lyons SK, Majidi S, Wood JR, Acharya R, Aleppo G, Sumpter KM, Cymbaluk A, Shah NA, Van Name M, Cruz-Aviles L, Alonso GT, Gallagher MP, Sanda S, Feuer AJ, Cossen K, Rioles N, Jones NY, Kamboj MK, Hirsch IB. Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers. The Journal Of Clinical Endocrinology & Metabolism 2020, 106: 1755-1762. PMID: 33410917, PMCID: PMC7928931, DOI: 10.1210/clinem/dgaa920.Peer-Reviewed Original ResearchConceptsNH Black patientsLaboratory-confirmed COVID-19NH-White patientsDiabetic ketoacidosisType 1 diabetesNH blacksBlack patientsNH whitesWhite patientsHispanic patientsPotential confoundersLaboratory-confirmed coronavirus disease 2019COVID-19Multivariable logistic regression analysisUS clinical centersCross-sectional studyCOVID-19 infectionCoronavirus disease 2019Logistic regression analysisRace/ethnicity groupsMedian HbA1cSerious complicationsDKA eventsPatient factorsT1D patientsHealth Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study
Weinstock R, Braffett B, Songer T, Herman W, Kuo S, Gubitosi-Klug R, Laffel L, McKay S, Siska M, Van Name M, Zeitler P. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care 2020, 43: 2469-2477. PMID: 32778555, PMCID: PMC7510035, DOI: 10.2337/dc20-0760.Peer-Reviewed Original ResearchConceptsType 2 diabetesHealth care coverageCare coverageGlycemic controlYoung adultsYouth-onset type 2 diabetesCommunity careYouth-Onset Type 2Medicaid expansionCommercial coverageCommunity diabetes careGovernment coverageDiabetes careDiabetes visitsTreatment optionsMore young adultsNew therapiesType 2DiabetesTODAY cohortCentral laboratoryVulnerable populationsCareCommercial plansHbAA Low ω-6 to ω-3 PUFA Ratio (n–6:n–3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth
Van Name MA, Savoye M, Chick JM, Galuppo BT, Feldstein AE, Pierpont B, Johnson C, Shabanova V, Ekong U, Valentino PL, Kim G, Caprio S, Santoro N. A Low ω-6 to ω-3 PUFA Ratio (n–6:n–3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. Journal Of Nutrition 2020, 150: 2314-2321. PMID: 32652034, PMCID: PMC7467848, DOI: 10.1093/jn/nxaa183.Peer-Reviewed Original ResearchConceptsFatty liver diseasePNPLA3 rs738409 genotypeLiver diseaseAlanine aminotransferaseRs738409 genotypeInsulin sensitivityObese youthNonalcoholic fatty liver diseaseGenotype groupsWhole-body insulin sensitivityBody insulin sensitivityLinoleic acid metabolitesHepatic fat fractionMann-Whitney U testDiet imbalanceNormocaloric dietPrimary outcomeLDL cholesterolDietary interventionFatty liverUnblinded studyObese adolescentsPUFA dietMetabolic parametersStable weightAlcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange
Alessi SM, Foster NC, Rash CJ, Van Name MA, Tamborlane WV, Cengiz E, Polsky S, Wagner J. Alcohol Use and Clinical Outcomes in Adults in the Type 1 Diabetes Exchange. Canadian Journal Of Diabetes 2020, 44: 501-506. PMID: 32792103, DOI: 10.1016/j.jcjd.2020.06.005.Peer-Reviewed Original ResearchConceptsBody mass indexSevere hypoglycemiaFormer drinkersLower oddsAlcohol consumptionNonbinge drinkersType 1Current binge drinkersPresence of neuropathyDiabetes-related distressDiabetes-related outcomesType 1 diabetesCross-sectional studyYears of ageNon-Hispanic whitesDiabetic ketoacidosisRecent severe hypoglycemiaMedical chartsClinical outcomesMass indexProspective studyDiabetes distressBlood glucoseBinge drinkersDrinking statusTransforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Van Name M, Klingensmith G, Nelson B, Wintergerst K, Mitchell J, Norris K, Tamborlane W, Clements M, Hannon T, Shoemaker A, Wood J, Gal R. Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. Diabetes Technology & Therapeutics 2020, 22: 330-336. PMID: 31859529, PMCID: PMC7869879, DOI: 10.1089/dia.2019.0448.Peer-Reviewed Original ResearchConceptsPediatric Diabetes ConsortiumType 2 diabetesClinical centersCoordinating CenterPediatric treatment centerPediatric type 1 diabetesPhase 3 trialType 2 Diabetes StudyType 1 diabetesPediatric Type 2Diabetes-related studiesTreatment of youthPivotal trialsRandomized subjectsDiabetes StudyStudy protocolClinical trialsContract research organizationsConsortium modelTreatment centersType 2DiabetesNew drugsTrialsEnrollment strategiesTime spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study
DiMeglio LA, Kanapka LG, DeSalvo DJ, Anderson BJ, Harrington KR, Hilliard ME, Laffel LM, Tamborlane WV, Van Name MA, Wadwa RP, Willi SM, Woerner S, Wong JC, Miller KM, Group F. Time spent outside of target glucose range for young children with type 1 diabetes: a continuous glucose monitor study. Diabetic Medicine 2020, 37: 1308-1315. PMID: 32096282, PMCID: PMC9065795, DOI: 10.1111/dme.14276.Peer-Reviewed Original ResearchSources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes
Commissariat P, Whitehouse A, Hilliard M, Miller KM, Harrington KR, Levy W, DeSalvo DJ, Van Name M, Anderson B, Tamborlane W, DiMeglio LA, Laffel L. Sources and Valence of Information Impacting Parents' Decisions to Use Diabetes Technologies in Young Children <8 Years Old with Type 1 Diabetes. Diabetes Technology & Therapeutics 2020, 22: 697-700. PMID: 32077755, PMCID: PMC7718841, DOI: 10.1089/dia.2019.0497.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes technologyCare providersYoung childrenDiabetes care providersHealth care providersCaregivers of childrenDiabetes technology useSubset of parentsDiabetesCare optionsType 1Most parentsUnderwent content analysisChildrenParents' decisionsProvidersSemi-structured interviewsParentsYearsChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
“I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes
Commissariat PV, Harrington KR, Whitehouse AL, Miller KM, Hilliard ME, Van Name M, DeSalvo DJ, Tamborlane WV, Anderson BJ, DiMeglio LA, Laffel LM. “I'm essentially his pancreas”: Parent perceptions of diabetes burden and opportunities to reduce burden in the care of children <8 years old with type 1 diabetes. Pediatric Diabetes 2019, 21: 377-383. PMID: 31808586, PMCID: PMC7830825, DOI: 10.1111/pedi.12956.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlycemic controlDiabetes burdenSecondary caregiversEmotional burdenChildren's glycemic controlYoung childrenCare of childrenAge 5.2Parents' perceptionsCaregivers' knowledgeClinical centersSemi-structured qualitative interviewsDiabetesDiabetes educationParental burdenHealthcare providersAge groupsInsulin pumpParents' burdenT1DChildren's qualityChild's diabetesParents' knowledgeParents' confidenceGreater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring
Van Name MA, Miller KM, Commissariat PV, Whitehouse AL, Harrington KR, Anderson BJ, Mantravadi MG, Levy W, DeSalvo DJ, Tamborlane WV, Hilliard ME, Laffel LM, DiMeglio LA. Greater parental comfort with lower glucose targets in young children with Type 1 diabetes using continuous glucose monitoring. Diabetic Medicine 2019, 36: 1508-1510. PMID: 31295359, PMCID: PMC7027357, DOI: 10.1111/dme.14074.Peer-Reviewed Original ResearchBenefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes
Hilliard ME, Levy W, Anderson BJ, Whitehouse AL, Commissariat PV, Harrington KR, Laffel LM, Miller KM, Van Name M, Tamborlane WV, DeSalvo DJ, DiMeglio LA. Benefits and Barriers of Continuous Glucose Monitoring in Young Children with Type 1 Diabetes. Diabetes Technology & Therapeutics 2019, 21: 493-498. PMID: 31287721, PMCID: PMC6708264, DOI: 10.1089/dia.2019.0142.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringCGM useDiabetes managementDiabetes careBenefits of CGMYoung childrenGlucose monitoringMean child ageChildren's diabetes careType 1 diabetes managementPainful insertionT1D durationParents of childrenGlucose excursionsImproved sleepClinical strategiesSemistructured qualitative interviewsType 1Parental comfortChild's ageChildrenBehavioural supportMultiple barriersParents' experiencesCaregiversFructose Consumption Contributes to Hyperinsulinemia in Adolescents With Obesity Through a GLP-1–Mediated Mechanism
Galderisi A, Giannini C, Van Name M, Caprio S. Fructose Consumption Contributes to Hyperinsulinemia in Adolescents With Obesity Through a GLP-1–Mediated Mechanism. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 3481-3490. PMID: 30938760, PMCID: PMC6599430, DOI: 10.1210/jc.2019-00161.Peer-Reviewed Original ResearchConceptsLean adolescentsGLP-1Insulin responseFructose consumptionBaseline oral glucose tolerance testGlucagon-like peptide-1 secretionOral glucose tolerance testGlucose-dependent insulinotropic polypeptideHigher GLP-1Plasma glucose excursionsGLP-1 responsePeptide-1 secretionGlucose tolerance testIngestion of glucoseΒ-cell functionMeasures of glucoseEligible subjectsGlucose ingestionGlucose toleranceLean adultsAnorexic effectFructose challengeGreater insulinInsulinotropic polypeptideLean group
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollment
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrateManagement and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes
Harrington KR, Boyle CT, Miller KM, Hilliard ME, Anderson BJ, Van Name M, DiMeglio LA, Laffel LM. Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes. Journal Of Diabetes Science And Technology 2017, 11: 980-987. PMID: 28770627, PMCID: PMC5951003, DOI: 10.1177/1932296817721938.Peer-Reviewed Original ResearchConceptsType 1 diabetesDiabetes managementT1D Exchange Clinic RegistryDuration of diabetesMean hemoglobin A1cFamily impact scoresLow blood sugarQuality of sleepYoung childrenMedical record informationClinical characteristicsHemoglobin A1cSerious complicationsBlood sugarClinic registryMean ageFamily burdenSubstantial burdenParental burdenDiabetesAge groupsInsulin pumpType 1Parents of youthChildren's diabetes management